Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies.

Conclusions: Treatment with fulranumab was generally tolerated with no new safety signals. Within the limited sample analyzed, fulranumab showed evidence of improvement of pain and function in patients with moderate-to-severe osteoarthritis who had failed prior therapy and were candidates for joint replacement surgery. Fulranumab as adjuvant or monotherapy was well tolerated with no new safety signals Fulranumab demonstrated evidence suggestive of efficacy in osteoarthritic pain of hip and knee Fulranumab demonstrated evidence suggestive of improvement of pain and physical function in osteoarthritis. PMID: 31387410 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research